Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MIA3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MIA3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MIA3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MIA3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MIA3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00901144 | Prostate | BPH | COPII-coated vesicle budding | 13/3107 | 29/18723 | 3.41e-04 | 2.54e-03 | 13 |
GO:000715910 | Prostate | BPH | leukocyte cell-cell adhesion | 86/3107 | 371/18723 | 5.95e-04 | 4.11e-03 | 86 |
GO:190303710 | Prostate | BPH | regulation of leukocyte cell-cell adhesion | 78/3107 | 336/18723 | 9.95e-04 | 6.25e-03 | 78 |
GO:00070293 | Prostate | BPH | endoplasmic reticulum organization | 26/3107 | 87/18723 | 1.45e-03 | 8.61e-03 | 26 |
GO:00716928 | Prostate | BPH | protein localization to extracellular region | 82/3107 | 368/18723 | 2.59e-03 | 1.39e-02 | 82 |
GO:00093069 | Prostate | BPH | protein secretion | 80/3107 | 359/18723 | 2.89e-03 | 1.52e-02 | 80 |
GO:00355929 | Prostate | BPH | establishment of protein localization to extracellular region | 80/3107 | 360/18723 | 3.13e-03 | 1.63e-02 | 80 |
GO:00435343 | Prostate | BPH | blood vessel endothelial cell migration | 43/3107 | 176/18723 | 4.79e-03 | 2.29e-02 | 43 |
GO:00509009 | Prostate | BPH | leukocyte migration | 80/3107 | 369/18723 | 6.09e-03 | 2.80e-02 | 80 |
GO:00716757 | Prostate | BPH | regulation of mononuclear cell migration | 30/3107 | 115/18723 | 6.38e-03 | 2.90e-02 | 30 |
GO:000268710 | Prostate | BPH | positive regulation of leukocyte migration | 34/3107 | 135/18723 | 6.93e-03 | 3.11e-02 | 34 |
GO:00224085 | Prostate | BPH | negative regulation of cell-cell adhesion | 46/3107 | 196/18723 | 7.95e-03 | 3.47e-02 | 46 |
GO:00026859 | Prostate | BPH | regulation of leukocyte migration | 48/3107 | 210/18723 | 1.13e-02 | 4.60e-02 | 48 |
GO:004819314 | Prostate | Tumor | Golgi vesicle transport | 105/3246 | 296/18723 | 3.55e-14 | 4.33e-12 | 105 |
GO:004206019 | Prostate | Tumor | wound healing | 127/3246 | 422/18723 | 5.32e-11 | 3.41e-09 | 127 |
GO:007097216 | Prostate | Tumor | protein localization to endoplasmic reticulum | 36/3246 | 74/18723 | 5.66e-10 | 2.95e-08 | 36 |
GO:000690018 | Prostate | Tumor | vesicle budding from membrane | 31/3246 | 61/18723 | 2.26e-09 | 9.64e-08 | 31 |
GO:009013217 | Prostate | Tumor | epithelium migration | 105/3246 | 360/18723 | 1.57e-08 | 5.62e-07 | 105 |
GO:009013017 | Prostate | Tumor | tissue migration | 106/3246 | 365/18723 | 1.73e-08 | 6.10e-07 | 106 |
GO:001063117 | Prostate | Tumor | epithelial cell migration | 104/3246 | 357/18723 | 1.97e-08 | 6.91e-07 | 104 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MIA3 | SNV | Missense_Mutation | | c.1863N>T | p.Glu621Asp | p.E621D | Q5JRA6 | protein_coding | tolerated(0.12) | benign(0.007) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIA3 | SNV | Missense_Mutation | | c.3776C>G | p.Ser1259Cys | p.S1259C | Q5JRA6 | protein_coding | deleterious(0.03) | probably_damaging(0.94) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MIA3 | SNV | Missense_Mutation | novel | c.2476N>C | p.Glu826Gln | p.E826Q | Q5JRA6 | protein_coding | tolerated(0.13) | benign(0.131) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MIA3 | SNV | Missense_Mutation | novel | c.3970N>A | p.Glu1324Lys | p.E1324K | Q5JRA6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MIA3 | SNV | Missense_Mutation | | c.1836N>T | p.Glu612Asp | p.E612D | Q5JRA6 | protein_coding | tolerated(0.12) | possibly_damaging(0.681) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIA3 | SNV | Missense_Mutation | rs199732400 | c.1159A>G | p.Ile387Val | p.I387V | Q5JRA6 | protein_coding | tolerated(0.57) | benign(0) | TCGA-B6-A2IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MIA3 | SNV | Missense_Mutation | | c.4900G>A | p.Ala1634Thr | p.A1634T | Q5JRA6 | protein_coding | tolerated(0.05) | possibly_damaging(0.802) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIA3 | SNV | Missense_Mutation | | c.3496N>C | p.Asp1166His | p.D1166H | Q5JRA6 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MIA3 | SNV | Missense_Mutation | | c.815N>G | p.Thr272Ser | p.T272S | Q5JRA6 | protein_coding | tolerated(0.38) | benign(0.031) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
MIA3 | SNV | Missense_Mutation | | c.1276G>A | p.Gly426Arg | p.G426R | Q5JRA6 | protein_coding | tolerated(0.48) | benign(0.009) | TCGA-C8-A131-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |